Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Bought by Russell Investments Group Ltd.

Russell Investments Group Ltd. lifted its stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 33.8% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 204,447 shares of the company's stock after purchasing an additional 51,601 shares during the quarter. Russell Investments Group Ltd.'s holdings in Teva Pharmaceutical Industries were worth $4,506,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. Clal Insurance Enterprises Holdings Ltd lifted its holdings in shares of Teva Pharmaceutical Industries by 12.8% in the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 38,962,773 shares of the company's stock worth $859,935,000 after acquiring an additional 4,418,961 shares during the last quarter. Todd Asset Management LLC purchased a new position in shares of Teva Pharmaceutical Industries during the fourth quarter valued at approximately $58,243,000. Raymond James Financial Inc. bought a new position in shares of Teva Pharmaceutical Industries during the fourth quarter valued at approximately $38,914,000. Norges Bank bought a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter worth approximately $38,550,000. Finally, AustralianSuper Pty Ltd boosted its stake in shares of Teva Pharmaceutical Industries by 16.8% during the fourth quarter. AustralianSuper Pty Ltd now owns 9,222,695 shares of the company's stock valued at $203,268,000 after purchasing an additional 1,329,319 shares during the period. Hedge funds and other institutional investors own 54.05% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on TEVA. UBS Group lowered their price target on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a "buy" rating for the company in a report on Thursday, January 30th. Barclays lowered their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a research note on Thursday, January 30th. Bank of America reduced their price target on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a "buy" rating for the company in a report on Thursday, March 6th. Piper Sandler lifted their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an "overweight" rating in a report on Friday, January 17th. Finally, StockNews.com lowered Teva Pharmaceutical Industries from a "buy" rating to a "hold" rating in a report on Monday, April 14th. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $23.43.

Teva Pharmaceutical Industries Stock Performance

Shares of NYSE TEVA traded up $0.18 during midday trading on Friday, reaching $13.61. The company had a trading volume of 8,836,138 shares, compared to its average volume of 9,903,611. The stock has a market cap of $15.43 billion, a P/E ratio of -9.38, a P/E/G ratio of 1.44 and a beta of 0.72. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97. Teva Pharmaceutical Industries Limited has a 1 year low of $12.47 and a 1 year high of $22.80. The business's 50-day simple moving average is $15.45 and its 200 day simple moving average is $17.67.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, beating analysts' consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. On average, analysts forecast that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.